Eyecelerator, a partner of the American Academy of Ophthalmology, is self-described as having the goal of advancing eye care ...
Preoperative identification and eradication of Demodex can improve ocular-surface comfort and may mitigate cataract-surgery ...
Dr. Khanani reviews 52-week safety outcomes, noting Axpaxli was generally well tolerated with no cases of endophthalmitis or retinal vasculitis. Dr. Khanani reviews 52-week safety outcomes, noting ...
Christopher E. Starr, MD, FACS, highlights diagnostic gaps in dry eye, emphasizing neuropathic corneal pain and reviewing ...
CME courses and educational resources on Ophthalmology Times - Clinical Insights for Eye Specialists ...
Oculis Holding AG announced that the final patient visit has been completed in the DIAMOND phase 3 program assessing OCS-01, ...
Pineless is the Jerome and Joan Snyder Chair in Ophthalmology and director of the Residency Program at the University of California, Los Angeles Stein Eye Institute. She practices pediatric and ...
Propensity-matched analyses showed smokers had significantly higher risk across all studied ocular outcomes over 10 years, ...
Self-reported hearing impairment reduced the likelihood of achieving clinically meaningful functional improvement after ...
New 52-week analyses from the phase 3 SOL-1 trial suggest that the investigational intravitreal therapy AXPAXLI (OTX-TKI) may ...
Michaelides is professor at UCL Institute of Ophthalmology and Moorfields Eye Hospital, London.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results